Treatment-naive patients with chronic lymphocytic leukemia who took Genentech's experimental drug GA-101, or obinutuzumab, in combination with chlorambucil, survived significantly longer without their disease worsening compared with patients who took chlorambucil alone, a late-stage trial found. Genentech plans to submit this trial's data to U.S. and European regulators for potential approval.

Related Summaries